Drugs / CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05277753 | Jun 2026 → Dec 2029 expected | T-cell acute lymphoblastic leukemia | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05277753 ↗ |
| Modality | Cell therapy | “multi-antigen-targeted chimeric antigen receptor T cells (CAR-T)” NCT05277753 ↗ |